Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

Science

Volumn 272, Issue 5270, 1996, Pages 1939-1943

  Levine, Bruce L ^a   Mosca, Joseph D ^b   Riley, James L ^c   Carroll, Richard G ^b   Vahey, Maryanne T ^c   Jagodzinski, Linda L ^b   Wagner, Kenneth F ^b   Mayers, Douglas L ^a,c   Burke, Donald S ^c   Weislow, Owen S ^d   St Louis, Daniel C ^b   June, Carl H ^a  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d SRA Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA INTEGRATION; GENE THERAPY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 8944232102     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.272.5270.1939     Document Type: Article

References (49)

1. S. M. Schnittman et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6058 (1990).
2. T. Seshamma, O. Bagasra, D. Trono, D. Baltimore, R. J. Pomerantz, ibid. 89, 10663 (1992).
3. M. I. Johnston and D. F. Hoth, Science 260, 1286 (1993); D. S. Stein, J. G. Timpone, J. D. Gradon, J. M. Kagan, S. M. Schnittman, Clin. Infect. Dis. 17, 749 (1993).
4. M. I. Johnston and D. F. Hoth, Science 260, 1286 (1993); D. S. Stein, J. G. Timpone, J. D. Gradon, J. M. Kagan, S. M. Schnittman, Clin. Infect. Dis. 17, 749 (1993).
5. J. B. Margolick, D. J. Volkman, H. C. Lane, A. S. Fauci, J. Clin. Invest. 76, 709 (1985); E. Maggi et al., Eur. J. Immunol. 17, 1685 (1987); G. Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, J. Immunol. 144, 1696 (1990).
6. J. B. Margolick, D. J. Volkman, H. C. Lane, A. S. Fauci, J. Clin. Invest. 76, 709 (1985); E. Maggi et al., Eur. J. Immunol. 17, 1685 (1987); G. Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, J. Immunol. 144, 1696 (1990).
7. J. B. Margolick, D. J. Volkman, H. C. Lane, A. S. Fauci, J. Clin. Invest. 76, 709 (1985); E. Maggi et al., Eur. J. Immunol. 17, 1685 (1987); G. Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, J. Immunol. 144, 1696 (1990).
8. P. S. Linsley and J. A. Ledbetter. Annu. Rev. Immunol. 11, 191 (1993); C. H. June, J. A. Bluestone, L. M. Nadler, C. B. Thompson, Immunol. Today 15, 321 (1994).
9. P. S. Linsley and J. A. Ledbetter. Annu. Rev. Immunol. 11, 191 (1993); C. H. June, J. A. Bluestone, L. M. Nadler, C. B. Thompson, Immunol. Today 15, 321 (1994).
10. H. Groux et al., J. Exp. Med. 175, 331 (1992); L. H. Boise et al., Immunity 3, 87 (1995).
11. H. Groux et al., J. Exp. Med. 175, 331 (1992); L. H. Boise et al., Immunity 3, 87 (1995).
12. B. L. Levine, Y. Ueda, N. Craighead, M. L. Huang, C. H. June, Int. Immunol. 7, 891 (1995); B. L. Levine, N. Craighead, T. Lindsten. C. B. Thompson, C. H. June, unpublished data.
13. B. L. Levine, Y. Ueda, N. Craighead, M. L. Huang, C. H. June, Int. Immunol. 7, 891 (1995); B. L. Levine, N. Craighead, T. Lindsten. C. B. Thompson, C. H. June, unpublished data.
14. B. L. Levine et al., data not shown.
15. B. L. Levine, J. D. Mosca, J. L. Riley, R. G. Carroll, O. S. Weislow, D. C. St. Louis, C. H. June, unpublished data.
16. + lymphocytes at culture termination.
17. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
18. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
19. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
20. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
21. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
22. H2 development [J. A. Bluestone, Immunity 2, 555 (1995); C. B. Thompson, Cell 81, 979 (1995)].
23. Cytokine secretion was tested in cultures from eight patients in Table 1 after 10 to 20 days in culture. Cells were collected and washed, and the extent of cytokine secretion upon restimulation was determined by placing the cells into fresh medium with beads coated with CD3 and CD28 mAbs for 24 hours. Cell-free culture supernatants were analyzed for IL-2, IFN-γ, IL-4, IL-5, and TNF-α by ELISA with the use of commercially available kits [T Cell Diagnostics, Woburn, MA (IL-2); R&D Systems, Minneapolis (TNF-α, IL-4, and IL-5); Endogen, Boston (IFN-γ)].
24. F. Cocchi et al., Science 270, 1811 (1995).
25. B. Asjo, D. Cefai, P. Debre, Y. Dudoit, B. Autran, J. Virol. 67, 4395 (1993); M. D. Smithgall, J. G. P. Wong, P. S. Linsley, O. K. Haffar, AIDS Res. Hum. Retroviruses 11, 885 (1995); L. M. Pinchuk, P. S. Polacino, M. B. Agy, S. J. Klaus, E. A. Clark, Immunity 1, 317 (1994).
26. B. Asjo, D. Cefai, P. Debre, Y. Dudoit, B. Autran, J. Virol. 67, 4395 (1993); M. D. Smithgall, J. G. P. Wong, P. S. Linsley, O. K. Haffar, AIDS Res. Hum. Retroviruses 11, 885 (1995); L. M. Pinchuk, P. S. Polacino, M. B. Agy, S. J. Klaus, E. A. Clark, Immunity 1, 317 (1994).
27. B. Asjo, D. Cefai, P. Debre, Y. Dudoit, B. Autran, J. Virol. 67, 4395 (1993); M. D. Smithgall, J. G. P. Wong, P. S. Linsley, O. K. Haffar, AIDS Res. Hum. Retroviruses 11, 885 (1995); L. M. Pinchuk, P. S. Polacino, M. B. Agy, S. J. Klaus, E. A. Clark, Immunity 1, 317 (1994).
28. CD4 cells have a hierarchy of permissiveness to HIV-1 infection that is determined by the mode of stimulation with various mitogens. In most donors, the susceptibility to HIV-1 infection is [soluble CD3 mAb, soluble CD28 mAb] → [concanavalin A, PHA] → [immobilized CD3 mAb, soluble CD28 mAb] → [immobilized CDS mAb, immobilized CD28 mAb]. The increased susceptibility of CD4 cells to HIV infection after stimulation with soluble antibody has been noted previously (14).
29. J. A. Nunes, Y. Collette, A. Truneh, D. Olive, D. A. Cantrell, J. Exp. Med. 180, 1067 (1994); J. A. Ledbetter et al., Blood 75, 1531 (1990).
30. J. A. Nunes, Y. Collette, A. Truneh, D. Olive, D. A. Cantrell, J. Exp. Med. 180, 1067 (1994); J. A. Ledbetter et al., Blood 75, 1531 (1990).
31. We have considered whether the antiviral effect mediated by CD28 costimulation might be a soluble factor or factors previously described by others [C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, Science 234, 1563 (1986)]. Given that the factor first described by Levy is secreted by CD8 cells and suppresses viral replication late in the viral life cycle, it is likely that the CD28 effect we have described is distinct. First, as shown in Table 2, the effect mediated by CD28 requires <0.6% CD8 cells, and thus it is either independent of CD8 T cells or dependent on trace amounts of CD8 cells. Second, the CD28 effect acts early in the viral life cycle to prevent infection of CD4, whereas the effect first described by Levy is reported to act late in the viral life cycle to suppress infection. Third, Cocchi et al. (13) have reported that chemokines are the major mediator of the CD8 antiviral effect, and we have found that the secretion of C-C chemokines is not dependent on CD28 stimulation (9).
32. A. Cayota, F. Vuillier, D. Scott-Algara, V. Feuillie, G. Dighiero, Clin. Exp. Immunol. 91, 241 (1993).
33. N. Weng, B. L. Levine, C. H. June, R. J. Hodes, Proc. Natl. Acad. Sci. U.S.A. 92, 11091 (1995); C. H. June, J. A. Ledbetter, M. M. Gillespie, T. Lindsten, C. B. Thompson, Mol. Cell Biol. 7, 4472 (1987).
34. N. Weng, B. L. Levine, C. H. June, R. J. Hodes, Proc. Natl. Acad. Sci. U.S.A. 92, 11091 (1995); C. H. June, J. A. Ledbetter, M. M. Gillespie, T. Lindsten, C. B. Thompson, Mol. Cell Biol. 7, 4472 (1987).
35. D. Dobrescu et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5563 (1995); J. Laurence, A. S. Hodtsev, D. N. Posnett, Nature 358, 255 (1992).
36. D. Dobrescu et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5563 (1995); J. Laurence, A. S. Hodtsev, D. N. Posnett, Nature 358, 255 (1992).
37. β12 population was 1.0 ± 0.4% on day 0 and 2.8 ± 1.4% at the end of the culture period (mean ± SD, P = 0.18).
38. N. J. Borthwick et al., AIDS 8, 431 (1994); J. E. Brinchmann et al., J. Infect. Dis. 169, 730 (1994): D. E. Lewis, D. S. Tang, A. Adu-Oppong, W. Schober, J. R. Rodgers, J. Immunol. 153, 412 (1994).
39. N. J. Borthwick et al., AIDS 8, 431 (1994); J. E. Brinchmann et al., J. Infect. Dis. 169, 730 (1994): D. E. Lewis, D. S. Tang, A. Adu-Oppong, W. Schober, J. R. Rodgers, J. Immunol. 153, 412 (1994).
40. N. J. Borthwick et al., AIDS 8, 431 (1994); J. E. Brinchmann et al., J. Infect. Dis. 169, 730 (1994): D. E. Lewis, D. S. Tang, A. Adu-Oppong, W. Schober, J. R. Rodgers, J. Immunol. 153, 412 (1994).
41. E. Maggi et al., Science 265, 244 (1994).
42. C. C. Wilson et al., J. Infect. Dis. 172, 88 (1995).
43. The CD4 percentage on day O of culture was not obtained for patients 5 and 9 because of limited cell availability; thus, the calculated cell proliferation is the actual cell proliferation without correction for the CD4 count, because only the final CD4 percentage was available.
44. M. T. Vahey, M. T. Wong, N. L. Michael, in PCR Primer: A Laboratory Manual, C. W. Dieffenbach and G. S. Dveksler, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1995), p. 17; M. T. Vahey and M. T. Wong, inibid., p. 313; N. L. Michael, M. Vahey, D. S. Burke, R. R. Redfield, J. Virol. 66, 310 (1992).
45. M. T. Vahey, M. T. Wong, N. L. Michael, in PCR Primer: A Laboratory Manual, C. W. Dieffenbach and G. S. Dveksler, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1995), p. 17; M. T. Vahey and M. T. Wong, inibid., p. 313; N. L. Michael, M. Vahey, D. S. Burke, R. R. Redfield, J. Virol. 66, 310 (1992).
46. M. T. Vahey, M. T. Wong, N. L. Michael, in PCR Primer: A Laboratory Manual, C. W. Dieffenbach and G. S. Dveksler, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1995), p. 17; M. T. Vahey and M. T. Wong, inibid., p. 313; N. L. Michael, M. Vahey, D. S. Burke, R. R. Redfield, J. Virol. 66, 310 (1992).
47. S. Gartner et al., Science 233, 215 (1986); J. R. Mascola et al., J. Infect. Dis. 169, 48 (1994).
48. S. Gartner et al., Science 233, 215 (1986); J. R. Mascola et al., J. Infect. Dis. 169, 48 (1994).
49. Supported by Army and Naval Medical Research and Development Commands grant 1437 and NIH grant A129331. We thank W. Bernstein and J. Lin for intellectual and experimental contributions; C. Thompson for manuscript review; D. Ritchey, S. Perfetto, D. Smoot, N. Craighead, J. Cotte, and S. Barrick for technical assistance; J. D. Malone and J, L. Malone for support and encouragement; clinic patients for blood donation; P. Ganong (Boehringer Ingelheim, Ridgefield, CT) for Nevirapine; and N. Peterson (Ortho Biotech, Raritan, NJ) for CD3 mAb OKT3. The views expressed in this report are those of the authors and do not reflect the official policy or position of the Departments of the Navy and Army, the Department of Defense, or the U.S. government.